Stay updated on Pralsetinib in RET+ Cancer Clinical Trial

Sign up to get notified when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pralsetinib in RET+ Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The revision badge at the bottom of the page updated from v3.6.2 to v3.6.3, indicating a minor update to the entry.
    Difference
    0.0%
    Check dated 2026-07-06T15:55:06.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    Footer shows Revision: v3.6.2, replacing the prior Revision: v3.6.0; the change represents a small system update rather than a modification to study data or page functionality.
    Difference
    0.0%
    Check dated 2026-06-29T08:37:16.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    The update shows recruitment has ended by displaying 'No longer looking for participants,' and adds help/navigation items such as 'How to Read a Study Record,' 'Common Questions,' and 'How to Join a Study,' along with minor label/version changes to 'Intervention/Treatment' and revision tags.
    Difference
    0.2%
    Check dated 2026-06-15T08:30:44.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    Revision tag on the page changed from v3.5.4 to v3.5.5. This indicates a minor system update to the ClinicalTrials.gov page rather than changes to the study details.
    Difference
    0.0%
    Check dated 2026-06-08T04:17:16.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.5.4, replacing the previous Revision: v3.5.3, indicating a minor platform update to the page without changing its content.
    Difference
    0.0%
    Check dated 2026-05-17T10:42:25.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    Adds a citation to NCCN Guidelines: Thyroid Carcinoma, Version 1.2025 (J Natl Compr Canc Netw. 2025). This reference provides guideline context for thyroid cancer management without altering the study’s core content.
    Difference
    0.0%
    Check dated 2026-05-10T11:02:38.000Z thumbnail image

Stay in the know with updates to Pralsetinib in RET+ Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.